ReviewThoracic cancer2023
Tumor size, but not consolidation-to-tumor ratio, is an independent prognostic factor for part-solid clinical T1 non-small cell lung cancer.
Review in Thoracic cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Deep learning-based computed tomography quantification integrated with circulating tumor cells for prognostic evaluation in stage I lung adenocarcinoma.Quantitative imaging in medicine and surgery · 2026Article
- The Relationship Between Pulmonary Spiculation and Central Fibrosis, Along With Other Clinicopathological Features, in Invasive Lung Adenocarcinoma and Its Prognostic Significance.Thoracic cancer · 2026Article
- Real-world efficacy of postoperative adjuvant EGFR-TKI therapy for stage IA2-IA3 lung adenocarcinoma with high-risk pathological factors.World journal of surgical oncology · 2025Article
- Value of serum LncRNA KIF9-AS1 combined with CT signs in the diagnosis of benign and malignant early pulmonary nodules and its correlation with prognosis.Journal of cardiothoracic surgery · 2025Article
- Development and evaluation of a nomogram prediction model for invasion and metastasis in primary liver cancer based on serum CD147 and IL-6.Frontiers in oncology · 2025Article
- Prognostic impact ofJournal of thoracic disease · 2024Article
- Exploring the impact of variable power outputs on the efficacy and safety during microwave ablation for lung carcinoma: a real-world study.Journal of thoracic disease · 2024Article
- Wedge resectionJournal of thoracic disease · 2024Article
- Preoperative systemic immune-inflammation index-based nomogram for lung carcinoma following microwave ablation -a real world single center study.Frontiers in oncology · 2024Article
- Segmentectomy versus lobectomy for small-sized pure solid non-small cell lung cancer.Thoracic cancer · 2023Article
- Tumor size, but not consolidation-to-tumor ratio, is an independent prognostic factor for part-solid clinical T1 non-small cell lung cancer.Thoracic cancer · 2023Review
- A rare case report: co-occurrence of two types of lung cancer with hamartoma and pulmonary tuberculosis.Frontiers in oncology · 2023Article
- Ensemble Machine Learning Classifiers Combining CT Radiomics and Clinical-Radiological Features for Preoperative Prediction of Pathological Invasiveness in Lung Adenocarcinoma Presenting as Part-Solid Nodules: A Multicenter Retrospective Study.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumor size and consolidation-to-tumor ratio (CTR) are crucial for non-small cell lung cancer (NSCLC) prognosis. However, the optimal CTR cutoff remains unclear. Whether tumor size and CTR are independent prognostic factors for part-solid NSCLC is under debate. Here, we aimed to evaluate the prognostic impacts of CTR and tumor size on NSCLC, especially on part-solid NSCLC.
methodsWe reviewed 1366 clinical T1 NSCLC patients who underwent surgical treatment. Log-rank test and Cox regression analyses were adopted for prognostic evaluation. The "surv_cutpoint" function was used to identify the optimal CTR and tumor size cutoff values.
resultsThere were 416, 510, and 440 subjects with pure ground-glass opacity (pGGO), part-solid, and pure solid nodules. The 5-year overall survival (disease-free survival) for patients with pGGO, part-solid, and pure solid nodules were 99.5% (99.5%), 97.3% (95.8%), and 90.4% (78.9%), respectively. Multivariate Cox regression analysis indicated that CTR was an independent prognostic factor for the whole patients, and the optimal CTR cutoff was 0.99. However, for part-solid NSCLC, CTR was not independently associated with survival, even if categorized by the optimal cutoffs. The predicted optimal cutoffs of total tumor size and solid component size were 2.4 and 1.4 cm for part-solid NSCLC. Total tumor size (HR = 6.21, 95% CI: 1.58-24.34, p = 0.009) and solid component size (HR = 2.27, 95% CI: 1.04-5.92, p = 0.045) grouped by the cutoffs were significantly associated with part-solid NSCLC prognosis.
conclusionsCTR was an independent prognostic factor for the whole NSCLC, but not for the part-solid NSCLC. Tumor size was still meaningful for part-solid NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.